organ uptick evid initi guidanc straddl street
reiter market outperform rate rais price target
follow releas result price
target appli premium price-to-earnings multipl prior ep
estim previous
believ share continu appreci consid compani
enhanc revenu growth opportun featur organ acceler
cc growth manag secular effort improv profit new
restructur initi announc today strong track record strateg
acquir leverag support anoth scale transact
essenti compani emerg large-cap play better prospect
time recal within last decad cover name
organ cc sale growth came y/i final quarter fiscal
volum contribut notabl excl surgic product line exit shipping-
day impact price account new product introduct ad
shipping-day impact gave anoth surgic product line exit
off-set sale quarter mln y/i cc
consensu mln adjust ep came y/
versu consensu
tfx segment broad posit quarterli perform highlight solid
growth vascular na cc intervent na cc emea cc
oem cc neotract strong momentum continu
mln y/i vascular solut grew y/i mln
drove compani segment cc y/i
manag offer initi full-year guidanc call sale growth
y/i cc impli bln dollar basi
adjust ep y/i consensu estim head
call revenu bln ep target
essenti bracket top-lin expect includ decreas caus
divestitur tfx surgic product line off-set recent
acquisit manta fx headwind mostli impact
first half year adjust ep growth driven oper leverag
acceler sale growth favor mix manufactur cost-reduct
turn quarterli margin perform compani gross oper
effici relat higher urolift intervent access sale volum
thomson reuter jmp secur llc
compani report jmp secur llc
report read conjunct import disclosur inform includ attest regul analyst certif
favor price posit fx benefit look gross margin
guidanc set bp oper margin
expect bp manag
comment invest growth opportun manta
launch urolift market develop japan expans urolift dtc
campaign creat headwind oper margin
near term contribut significantli compani long-term
segment basi cc y/i sale growth came follow vascular na grew
declin y/i emea grew asia grew oem grew
notabl point made call includ shonin approv
urolift japan novemb urolift newli publish real-world data
clearanc percuv pma approv februari
recent acquir manta product japanes approv came earlier
compani expect manag sinc decid acceler
pre-commerci invest order achiev limit launch mid-
would follow reimburs expect month
process result urolift real-world studi publish
decemb show signific improv bph consist
previou five-year studi mileston neotract product
includ posit reimburs coverag decis ad
mln live treatment patient symptom bph
recent pre-market approv manta first commerci avail
biomed capsular closur devic specif larg closur product
expect begin limit market releas
manag gave initi guidanc sale growth adjust ep margin follow
figur highlight key guidanc metric along select commentari
figur follow page highlight actual vs jmp estim rang revenu
metric along select commentari compani chang report segment therefor
previou estim applic mark na
rang bln expect headwind foreign exchang greatest impact urolog intervent access asia key contributor growth divestitur surgic product off-set recent acquisit includ mantagross intervent urolog intervent access capabl product mix expect continu benefit manufactur product improv program previous announc restructur programsoper margin ex increas bp rang includ proactiv invest support launch manta precommerci urolift market develop japan expans urolift dtc campaign result higher mix taxabl incom well normal sbc benefitadj gener signific level oper leverag acceler revenu growth favor mix manufactur cost-reduct init teleflex incorpor
 edeltacommentsvascular north america bpsintervent north bpsanesthesia north bpssurgic north bpstotal mlnannual bpsgross bp y/i primarili reflect effici relat higher urolift intervent access sale volum favor price posit impact bpsoper bp y/ytax bpsnet bpsadjust cc driven strong growth picc visual navig cc primarili result higher sale vascular solut product well growth cc growth driven airway ez-io cc impact decis exit low-margin surgic product caus mln headwind cc larg driven distributor convers acceler intervent access cc driven growth intervent access surgic product revenu strong within southeast asia japan china despit hard comp cc higher sale volum cathet perform fiber cc primarili due urolift growth mln teleflex incorpor
pure-play med-tech compani transform via merger acquisit number year industri
conglomer foray medic devic industri began late compani began use polym technolog
manufactur intraven cathet tube ultim sold oem grew medic segment late
acquisit rusch pill weck creat medic busi includ dispos
reusabl devic latex cathet endotrach tube laryngoscop face mask tracheotomi tube urolog
gastroenterolog anesthesiolog market well ligat gener surgic devic transform divest
non-med asset make number mostli bolt-on acquisit cap substanti bln purchas
late compani also purchas lma mln vidacar mln
invest thesi valuat subject number risk oper highli competit medic devic market character
price pressur ip disput medic devic highli regul compani fail fda inspect could receiv
warn letter potenti lose abil sell certain product company-specif front reli acquisit bolster
growth profil increas invest guarante acquisit pipelin product accret valu
compani abl execut oper effici program
research analyst prepar report does/do herebi certifi view present report accord my/our
person view secur issuer discuss report mandat sec regul ac part my/our compens
directli indirectli relat specif view recommend express herein certif made
oblig set forth sec regul ac person entiti may use purpos certif made
base my/our analysi date report public i/w assum oblig updat certif reflect fact
circumst event may subsequ come my/our attent sign david turkali daniel stauder
